Literature DB >> 27429790

Toxoplasma Gondii Infection and Depression: A Case-Control Seroprevalence Study.

Cosme Alvarado-Esquivel1, Luis Francisco Sánchez-Anguiano2, Jesús Hernández-Tinoco2, Luis Omar Berumen-Segovia1, Yazmin Elizabeth Torres-Prieto3, Sergio Estrada-Martínez2, Alma Rosa Pérez-Álamos2, María Nalleli Ortiz-Jurado4, Gabriel Molotla-de-León4, Isabel Beristain-García3, Elizabeth Rábago-Sánchez5, Oliver Liesenfeld6.   

Abstract

We assessed the association of Toxoplasma gondii infection and depression in a sample of psychiatric patients and control subjects without depression. We performed an age- and gender-matched case-control study of 89 patients suffering from depression attended in a public psychiatric hospital in Durango City, Mexico and 356 control subjects without depression from the general population of the same city. Participants were tested for the presence of anti-Toxoplasma IgG and IgM antibodies using enzyme-linked immunoassays. Anti-T. gondii IgG antibodies were found in 11 (12.4%) of the 89 cases and in 22 (6.2%) of the 356 controls (OR = 2.14; 95% CI: 1.00-4.59; P = 0.04). Anti-T. gondii IgM antibodies were found in four (19%) of 21 anti-T. gondii IgG seropositive controls but not in 11 anti-T. gondii IgG seropositive cases (P = 0.27). Patients aged 30 years old and younger had a significantly higher seroprevalence of T. gondii infection than controls of the same age group (P = 0.001). Results of the present study suggest a potential association between T. gondii infection and depression. Furthers studies to confirm our results and to determine the epidemiology of T. gondii in young depressed patients should be conducted.

Entities:  

Keywords:  Toxoplasmagondii; case–control study; depression; psychiatric patients; seroprevalence

Year:  2016        PMID: 27429790      PMCID: PMC4936330          DOI: 10.1556/1886.2016.00010

Source DB:  PubMed          Journal:  Eur J Microbiol Immunol (Bp)        ISSN: 2062-509X


Introduction

The coccidian parasite Toxoplasma gondii (T. gondii) causes infections all around the world [1]. Main routes of T. gondii infection are eating raw or under cooked meat containing tissue cysts, and ingestion of water contaminated with oocysts shed by cats [2, 3]. Infection with T. gondii can also occur vertically [2, 4]. Most infections with T. gondii are asymptomatic. However, infection with T. gondii may lead to eye, lymph node, and central nervous system disease, i.e., in congenital toxoplasmosis and in immunocompromised patients [2, 5, 6]. Seroprevalence of T. gondii is high in psychiatric patients in general [7, 8]. A number of mental illnesses have been linked to T. gondii infection including schizophrenia [9, 10], anxiety [11], and cognitive impairment [12-14]. There is controversy about an association of T. gondii infection and mood disorders. In a study of psychiatric patents in Cuba, researchers found the highest percentage of reactivity to the toxoplasmin intradermal test among patients with depressive mental disorders [15]. A case of depression with T. gondii seropositivity who responded to antidepressant treatment only after adequate treatment for T. gondii was reported [16]. However, in the Third National Health and Nutrition Survey in the USA, researchers did not find an association between T. gondii seroprevalence and history of major depression or dysthymia [17]. On the other hand, T. gondii antibody titers have been linked to suicide attempts in patients with recurrent mood disorders [18]. Therefore, we sought to determine the association between T. gondii infection and depression in patients attended in a public psychiatric hospital in Durango City, Mexico.

Materials and methods

Study design and patients studied

Through an age- and gender-matched case–control study design, we examined 89 psychiatric patients suffering from depression attended in a public psychiatric hospital in Durango, Mexico and 356 control subjects without depression from the general population of the same city. This study was performed from August to November 2015. Inclusion criteria for enrollment of cases were: 1) patients suffering from depression attended in the Hospital of Mental Health “Dr. Miguel Vallebueno” of the Secretary of Health in Durango City; 2) aged 17 years and older; and 3) who accepted to participate in the study. Gender was not a restrictive criterion for enrollment. Of the 89 cases, 64 (71.9%) were females and 25 (28.1%) were males. Mean age in cases was 38.65 ± 12.93 (range 17–78) years old. The diagnosis of depressive disorder was classified using the International Classification of Diseases (ICD-10) (http://www.who.int/classifications/icd/en/). Control subjects were matched with cases for gender and age. Controls were randomly selected from the general population of Durango City. Controls considered themselves as healthy without depression. Inclusion criteria for enrollment of controls were: 1) subjects of the general population of Durango City without depression; 2) aged 17 years and older; and 3) who accepted to participate in the study. Of the 356 controls, 260 (73.0%) were females and 96 (27.0%) were males. Mean age in controls was 38.66 ± 12.89 (range 17–80) years old. No statistically significant differences in age (P = 0.99) and gender (P = 0.83) between cases and controls were found.

Detection of anti-T. gondii antibodies

Serum samples from participants were obtained and stored at –20 °C until analyzed. Anti-T. gondii IgG antibodies were determined in sera with the commercially available enzyme immunoassay (EIA) kit “Toxoplasma IgG” (Diagnostic Automation/Cortez Diagnostics Inc., Woodland Hills, CA, USA). Anti-T. gondii IgG antibody levels were expressed as International Units (IU)/ml, and results ≥8 IU/ml were considered positive. Seropositive for anti-T. gondii IgG antibodies were further analyzed for anti-T. gondii IgM antibodies by the commercially available EIA “Toxoplasma IgM” kit (Diagnostic Automation/Cortez Diagnostics Inc.). All IgG and IgM assays were performed according to the instructions of the manufacturer.

Statistical analysis

We performed the statistical analysis with the aid of the software SPSS 15.0 (SPSS Inc., Chicago, Illinois) and Epi Info 7. For calculation of the sample size, we used a 95% confidence level, a power of 80%, a 1:4 proportion of cases and controls, a reference seroprevalence of 6.1% [19] as the expected frequency of exposure in controls, and an odds ratio of 3.3. The result of the sample size calculation was 67 cases and 268 controls. The student’s t test was used to compare the age among the groups. The association of T. gondii infection and depression was assessed with the two-tailed Pearson’s Chi-square test or the Fisher’s exact test (when cell values were less than 5). We calculated the odds ratio (OR) and 95% confidence interval (CI), and statistical significance was set at a P value of <0.05.

Ethical aspects

This study was approved by The Ethics Committee of the General Hospital of the Secretary of Health in Durango City, Mexico. The purpose and procedures of this case–control study were explained to all participants, and a written informed consent was obtained from all of them.

Results

Of the 89 cases of depression included in the study, 69 (77.5%) suffered from a depressive episode (ICD-10 code F32) and 20 (22.5%) from recurrent depressive disorders (ICD-10 code F33). shows the diagnoses of the patients studied and their correlation with T. gondii seroprevalence. Anti-T. gondii IgG antibodies were found in 11 (12.4%) of the 89 cases and in 22 (6.2%) of the 356 controls. The seroprevalence of T. gondii infection was significantly higher in cases than in controls (OR = 2.14; 95% CI: 1.00–4.59; P = 0.04). Of the 11 anti-T. gondii IgG positive cases, four (36.4%) had IgG levels higher than 150 IU/ml, one (9.1%) between 100 and 150 IU/ml, and six (54.5%) between 8 and 99 IU/ml. In comparison, of the 22 anti-T. gondii IgG positive controls, 11 (50.0%) had IgG levels higher than 150 IU/ml, one (4.5%) between 100 and 150 IU/ml, and ten (45.5%) between 8 and 99 IU/ml. The frequency of high (>150 IU/ml) anti-T. gondii IgG levels was similar in cases and controls (OR = 1.47; 95% CI: 0.45–4.74; P = 0.51). Seroprevalence of T. gondii infection did not vary with the types of depression diagnoses ( Patients with a depressive episode (ICD-10 code F32) had a similar seroprevalence of T. gondii than patients with recurrent depressive disorders (ICD-10 code F33) (8/69: 11.6% vs. 3/20: 15.0%; P = 0.70). Patients with mild forms of depression had the highest seroprevalence of T. gondii infection (mild depressive episode: 15.4%; mild recurrent depressive disorder: 23.1%). However, patients with mild depression had a comparable seroprevalence of T. gondii infection compared to patients with moderate, severe or in remission depression (9/52: 17.3% vs. 2/37: 5.4%; P = 0.11). Anti-T. gondii IgM antibodies were found in four (19%) of 21 anti-T. gondii IgG seropositive controls; none of the 11 anti-T. gondii IgG seropositive cases had anti-T. gondii IgM antibodies. There was not a statistically significant difference in the frequency of IgM seropositivity among cases and controls (P = 0.27). When results of the seroprevalence of T. gondii infection were collapsed by sex and age, we observed that seroprevalence did not vary with sex but with age groups. Patients aged 30 years old and younger had a significantly higher seroprevalence of T. gondii infection than controls of the same age group (P = 0.001) ( Seroprevalence did not vary between cases and controls in the age groups of 31–50 years and older than 50 years.

Discussion

Currently, there are fragmentary and sometimes conflicting results about the association of T. gondii infection and depression [15-17]. This study aimed to determine whether T. gondii seropositivity is associated with depression in Durango City, Mexico. Results of our study show that psychiatric patients suffering from depression have a significantly higher seroprevalence of T. gondii infection than control subjects without depression in the general population of the same city. Thus, results of this gender- and age-matched case–control seroprevalence provide further support for the association of T. gondii infection with depression as reported in other studies. In a study of 70 women veterans, significant associations between T. gondii seropositivity and the Center for Epidemiologic Studies Depression score, Profile for Mood States – depression, and total mood disturbance score were found [20]. In a study of pregnant women in the USA, prenatal depression was associated with higher T. gondii titers in infected women [21]. In addition, the report of a 32-year-old male suffering from depression with T. gondii seropositivity who responded to antidepressant treatment only after adequate treatment for T. gondii [16] supports the potential role of T. gondii in depression. In addition, patients suffering from bipolar disorder with positive serology to T. gondii treated with antipsychotic and/or mood stabilizers having known in vitro anti-Toxoplasmic activity had less depressive episodes than patients treated with drugs having no anti-Toxoplasmic activity [22]. On the other hand, researchers did not find a significant OR (1.21; P = 0.28) supporting the association of the presence of anti-T. gondii IgG antibodies and major depression in a meta-analysis [9]. Similarly, in the Third National Health and Nutrition Survey in the USA, no association between T. gondii seroprevalence and history of major depression was found [17]. These studies examined the association of T. gondii infection with major depression. However, in the present study, we examined the association of infection with mild, moderate, and severe forms of depression and did not find an association of T. gondii infection with severe depression. Instead, we found an association of infection with mild depression. However, since the present study only included a limited number of cases of severe depression (n = 15), further research with a larger number of cases with severe depression to elucidate the association of this disease with infection should be conducted. In the present study, seroprevalence of T. gondii infection was similar in male and female patients suffering from depression. In contrast, young patients (30 years old and younger) but not other age groups suffering from depression had a significantly higher seroprevalence than controls of the same age group. Of interest, the seroprevalence (17.9%) found in young patients suffering from depression is remarkably high in Durango City, and seroprevalence of T. gondii infection in patients with depression did not follow the typical increase with age. On the contrary, seroprevalence decreased from 17.9% in the youngest group to 6.7% in the oldest group (51 years and older). In addition, the seroprevalence in young patients with depression is much higher than those reported in subjects of the same age in other population groups in the same city studied; for instance, seroprevalences of T. gondii infection in subjects 30 years and younger were 4.3% in workers with occupational exposure to animals [23], 5.4% in fruit and vegetable workers [24], and 8% in meat workers [25]. Of note, none of the cases seropositive to T. gondii had IgM antibodies, suggesting that depression might be associated with latent infection. It is not clear how T. gondii causes depression. Tachyzoites of T. gondii invade a number of cells in brain [26]. It is possible that T. gondii causes mood disorders through changes in the levels of brain dopamine and serotonin [21]. The T. gondii genome contains two aromatic aminoacid hydroxylases that could affect dopamine and/or serotonin biosynthesis [27]. T. gondii could cause depression by affecting the tryptophan metabolism and the hypothalamic–pituitary–adrenal axis [27]. This study has limitations. The sample size of cases with depression was small. In addition, we studied only patients who sought medical care at the Hospital of Mental Health, and thus, results cannot be extrapolated to the general population. Comparison of T. gondii seroprevalence between depressed patients and patients suffering from psychiatric diseases other than depression is still needed. Further studies with a larger sample size of cases with depression and with population groups other than psychiatric inpatients (i.e., pregnant women, general population) to determine the association of T. gondii exposure and depression should be conducted.

Conclusions

Results of the present study suggest an association between T. gondii exposure and depression. Young depressed patients had the highest seroprevalence of T. gondii infection. Further studies to confirm our results and to determine the epidemiology of T. gondii exposure in young depressed patients should be conducted.
Table 1.

Correlation of depression diagnoses and seroprevalence of T. gondii infection in the patients studied

DiagnosesNo. testedT. gondii infectionP value
No.%
Mild depressive episode (F32.0)39615.40.70
Moderate depressive episode (F32.1)2627.7
Severe depressive episode (F32.2)400.0
Mild recurrent depressive disorder (F33.0)13323.1
Moderate recurrent depressive disorder (F33.1)300.0
Severe recurrent depressive disorder (F33.2)300.0
Recurrent depressive disorder in remission (F33.4)100.0
Table 2.

Comparison of seropositivity rate to T. gondii according to sex and age between cases and controls

CharacteristicsCasesControlsP value
No. testedSeroprevalence of T. gondii infectionNo. testedSeroprevalence of T. gondii infection
No.%No.%
Sex
    Male25416.09666.30.21
    Female64710.9260166.20.18
Age (years old)
    30 or less28517.911110.90.001
    31–5046510.9185179.20.77
    >501516.76046.71.0
  26 in total

1.  Toxoplasma gondii infection in workers occupationally exposed to raw meat.

Authors:  C Alvarado-Esquivel; O Liesenfeld; S Estrada-Martínez; J Félix-Huerta
Journal:  Occup Med (Lond)       Date:  2011-04-22       Impact factor: 1.611

Review 2.  Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis.

Authors:  A L Sutterland; G Fond; A Kuin; M W J Koeter; R Lutter; T van Gool; R Yolken; A Szoke; M Leboyer; L de Haan
Journal:  Acta Psychiatr Scand       Date:  2015-04-15       Impact factor: 6.392

Review 3.  Prevalence and risk factors for Toxoplasma gondii infection in meat animals and meat products destined for human consumption.

Authors:  Miao Guo; Jitender P Dubey; Dolores Hill; Robert L Buchanan; H Ray Gamble; Jeffrey L Jones; Abani K Pradhan
Journal:  J Food Prot       Date:  2015-02       Impact factor: 2.077

4.  Toxoplasma gondii impairs memory in infected seniors.

Authors:  Patrick D Gajewski; Michael Falkenstein; Jan G Hengstler; Klaus Golka
Journal:  Brain Behav Immun       Date:  2013-12-07       Impact factor: 7.217

Review 5.  [Toxoplasma gondii: a potential role in the genesis of psychiatric disorders].

Authors:  G Fond; D Capdevielle; A Macgregor; J Attal; A Larue; M Brittner; D Ducasse; J-P Boulenger
Journal:  Encephale       Date:  2012-08-21       Impact factor: 1.291

6.  Treatment with anti-toxoplasmic activity (TATA) for toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study.

Authors:  Guillaume Fond; Laurent Boyer; Alexandru Gaman; Hakim Laouamri; Dodji Attiba; Jean-Romain Richard; Marine Delavest; Josselin Houenou; Philippe Le Corvoisier; Dominique Charron; Rajagopal Krishnamoorthy; José Oliveira; Ryad Tamouza; Robert Yolken; Faith Dickerson; Marion Leboyer; Nora Hamdani
Journal:  J Psychiatr Res       Date:  2015-02-24       Impact factor: 4.791

Review 7.  Neuropsychiatric disease and Toxoplasma gondii infection.

Authors:  S A Henriquez; R Brett; J Alexander; J Pratt; C W Roberts
Journal:  Neuroimmunomodulation       Date:  2009-02-11       Impact factor: 2.492

Review 8.  Toxoplasmosis.

Authors:  J G Montoya; O Liesenfeld
Journal:  Lancet       Date:  2004-06-12       Impact factor: 79.321

9.  Seroprevalence and associated risk factors of Toxoplasma gondii infection in psychiatric patients: a case-control study in eastern China.

Authors:  W Cong; W Dong; L Bai; X-Y Wang; X-T Ni; A-D Qian; X-Q Zhu
Journal:  Epidemiol Infect       Date:  2015-02-17       Impact factor: 4.434

10.  Seroepidemiology of infection with Toxoplasma gondii in migrant agricultural workers living in poverty in Durango, Mexico.

Authors:  Cosme Alvarado-Esquivel; Federico Campillo-Ruiz; Oliver Liesenfeld
Journal:  Parasit Vectors       Date:  2013-04-20       Impact factor: 3.876

View more
  11 in total

1.  Positive association between Toxoplasma gondii IgG serointensity and current dysphoria/hopelessness scores in the Old Order Amish: a preliminary study.

Authors:  Abhishek Wadhawan; Aline Dagdag; Allyson Duffy; Melanie L Daue; Kathy A Ryan; Lisa A Brenner; John W Stiller; Toni I Pollin; Maureen W Groer; Xuemei Huang; Christopher A Lowry; Braxton D Mitchell; Teodor T Postolache
Journal:  Pteridines       Date:  2017-11-22       Impact factor: 0.581

2.  Toxoplasma gondii infection and insomnia: A case control seroprevalence study.

Authors:  Cosme Alvarado-Esquivel; Sergio Estrada-Martínez; Alma Rosa Pérez-Álamos; Agar Ramos-Nevárez; Karina Botello-Calderón; Ángel Osvaldo Alvarado-Félix; Raquel Vaquera-Enríquez; Gustavo Alexis Alvarado-Félix; Antonio Sifuentes-Álvarez; Carlos Alberto Guido-Arreola; Elizabeth Rábago-Sánchez; Leandro Saenz-Soto
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

3.  Association between Toxoplasma gondii infection and history of blood transfusion: a case-control seroprevalence study.

Authors:  Cosme Alvarado-Esquivel; Luis Francisco Sánchez-Anguiano; Jesús Hernández-Tinoco; Agar Ramos-Nevarez; Sergio Estrada-Martínez; Sandra Margarita Cerrillo-Soto; Gonzalo Elías Medina-Heredia; Carlos Alberto Guido-Arreola; Araceli Alejandra Soto-Quintero; Isabel Beristain-Garcia
Journal:  J Int Med Res       Date:  2018-03-01       Impact factor: 1.671

4.  Is there any association between Toxoplasma gondii infection and depression? A systematic review and meta-analysis.

Authors:  Tooran Nayeri Chegeni; Mehdi Sharif; Shahabeddin Sarvi; Mahmood Moosazadeh; Mahbobeh Montazeri; Sargis A Aghayan; Nader Jafari Balalami; Shirzad Gholami; Zahra Hosseininejad; Reza Saberi; Davood Anvari; Shaban Gohardehi; Ahmad Daryani
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

5.  A Case-Control Seroprevalence Study on the Association Between Toxoplasma gondii Infection and Bipolar Disorder.

Authors:  Cosme Alvarado-Esquivel; Sergio Estrada-Martínez; Alma Rosa Pérez-Alamos
Journal:  Front Psychiatry       Date:  2019-10-25       Impact factor: 4.157

6.  Seroepidemiology of Toxoplasma gondii infection in people with alcohol consumption in Durango, Mexico.

Authors:  Sergio Estrada-Martinez; Alma Rosa Pérez-Álamos; Melina Ibarra-Segovia; Isabel Beristaín-Garcia; Agar Ramos-Nevárez; Leandro Saenz-Soto; Elizabeth Rábago-Sánchez; Carlos Alberto Guido-Arreola; Cosme Alvarado-Esquivel
Journal:  PLoS One       Date:  2021-01-28       Impact factor: 3.240

7.  Association between depression and antibiotic use: analysis of population-based National Health Insurance claims data.

Authors:  Jong-Wook Lee; Hankil Lee; Hye-Young Kang
Journal:  BMC Psychiatry       Date:  2021-10-28       Impact factor: 3.630

8.  Toxoplasma gondii Infection in Patients with Psychiatric Disorders from Western Romania.

Authors:  Sebastian Grada; Alin Gabriel Mihu; Cristina Petrescu; Oana Suciu; Iosif Marincu; Maria Alina Lupu; Tudor Rares Olariu
Journal:  Medicina (Kaunas)       Date:  2022-01-30       Impact factor: 2.430

9.  The Association between Suicide Attempts and Toxoplasma gondii Infection.

Authors:  Jeongjae Bak; Se-Hoon Shim; Young-Joon Kwon; Hwa-Young Lee; Ji Sun Kim; Heejung Yoon; Yeon Jung Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-02-28       Impact factor: 2.582

Review 10.  Toxoplasma gondii, Suicidal Behavior, and Intermediate Phenotypes for Suicidal Behavior.

Authors:  Teodor T Postolache; Abhishek Wadhawan; Dan Rujescu; Andrew J Hoisington; Aline Dagdag; Enrique Baca-Garcia; Christopher A Lowry; Olaoluwa O Okusaga; Lisa A Brenner
Journal:  Front Psychiatry       Date:  2021-06-11       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.